Cargando…
Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate
Comirnaty™ and Spikevax™ were the first vaccines approved for human use based on modified non-replicating mRNA lipophilic nanoparticle (mRNA-LNP) technology, with great success in the treatment of COVID-19. They have been used massively worldwide. One of the major inconveniences of these vaccines is...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675537/ https://www.ncbi.nlm.nih.gov/pubmed/38005967 http://dx.doi.org/10.3390/vaccines11111635 |
_version_ | 1785141088374226944 |
---|---|
author | Hermosilla, Jesús Alonso-García, Airan Salmerón-García, Antonio Cabeza-Barrera, José Medina-Castillo, Antonio L. Pérez-Robles, Raquel Navas, Natalia |
author_facet | Hermosilla, Jesús Alonso-García, Airan Salmerón-García, Antonio Cabeza-Barrera, José Medina-Castillo, Antonio L. Pérez-Robles, Raquel Navas, Natalia |
author_sort | Hermosilla, Jesús |
collection | PubMed |
description | Comirnaty™ and Spikevax™ were the first vaccines approved for human use based on modified non-replicating mRNA lipophilic nanoparticle (mRNA-LNP) technology, with great success in the treatment of COVID-19. They have been used massively worldwide. One of the major inconveniences of these vaccines is related to pharmaceutical stability issues. Proper transportation, storage, and in-use handling before administration to patients are critical steps since failures can potentially reduce potency. In this research, the in-use stability of Comirnaty™ and Spikevax™ clinical samples was analysed and the results were compared. As changes in the size of the mRNA-LNPs are related to potency, these modifications were analysed by qualitative Dynamic Light Scattering (DLS) as a stability-indicating method for control and stressed vaccine samples. Strong stress factors (accelerated light irradiation, manual shaking, and vortex vibration) and conditions that mimic in-use handling (exposure to natural light and room temperature, repeated cycles of injections, and 24 h storage in syringes) were checked. The morphology of the mRNA-LNPs was analysed by Transmission Electron Microscopy (TEM) to better interpret and support the DLS results. Although the two vaccines are based on the same mRNA-LNP technology, the results demonstrate that they are characterised by very different particle size profiles and behaviours against different handling/stress conditions. |
format | Online Article Text |
id | pubmed-10675537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106755372023-10-25 Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate Hermosilla, Jesús Alonso-García, Airan Salmerón-García, Antonio Cabeza-Barrera, José Medina-Castillo, Antonio L. Pérez-Robles, Raquel Navas, Natalia Vaccines (Basel) Article Comirnaty™ and Spikevax™ were the first vaccines approved for human use based on modified non-replicating mRNA lipophilic nanoparticle (mRNA-LNP) technology, with great success in the treatment of COVID-19. They have been used massively worldwide. One of the major inconveniences of these vaccines is related to pharmaceutical stability issues. Proper transportation, storage, and in-use handling before administration to patients are critical steps since failures can potentially reduce potency. In this research, the in-use stability of Comirnaty™ and Spikevax™ clinical samples was analysed and the results were compared. As changes in the size of the mRNA-LNPs are related to potency, these modifications were analysed by qualitative Dynamic Light Scattering (DLS) as a stability-indicating method for control and stressed vaccine samples. Strong stress factors (accelerated light irradiation, manual shaking, and vortex vibration) and conditions that mimic in-use handling (exposure to natural light and room temperature, repeated cycles of injections, and 24 h storage in syringes) were checked. The morphology of the mRNA-LNPs was analysed by Transmission Electron Microscopy (TEM) to better interpret and support the DLS results. Although the two vaccines are based on the same mRNA-LNP technology, the results demonstrate that they are characterised by very different particle size profiles and behaviours against different handling/stress conditions. MDPI 2023-10-25 /pmc/articles/PMC10675537/ /pubmed/38005967 http://dx.doi.org/10.3390/vaccines11111635 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hermosilla, Jesús Alonso-García, Airan Salmerón-García, Antonio Cabeza-Barrera, José Medina-Castillo, Antonio L. Pérez-Robles, Raquel Navas, Natalia Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate |
title | Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate |
title_full | Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate |
title_fullStr | Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate |
title_full_unstemmed | Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate |
title_short | Analysing the In-Use Stability of mRNA-LNP COVID-19 Vaccines Comirnaty™ (Pfizer) and Spikevax™ (Moderna): A Comparative Study of the Particulate |
title_sort | analysing the in-use stability of mrna-lnp covid-19 vaccines comirnaty™ (pfizer) and spikevax™ (moderna): a comparative study of the particulate |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675537/ https://www.ncbi.nlm.nih.gov/pubmed/38005967 http://dx.doi.org/10.3390/vaccines11111635 |
work_keys_str_mv | AT hermosillajesus analysingtheinusestabilityofmrnalnpcovid19vaccinescomirnatypfizerandspikevaxmodernaacomparativestudyoftheparticulate AT alonsogarciaairan analysingtheinusestabilityofmrnalnpcovid19vaccinescomirnatypfizerandspikevaxmodernaacomparativestudyoftheparticulate AT salmerongarciaantonio analysingtheinusestabilityofmrnalnpcovid19vaccinescomirnatypfizerandspikevaxmodernaacomparativestudyoftheparticulate AT cabezabarrerajose analysingtheinusestabilityofmrnalnpcovid19vaccinescomirnatypfizerandspikevaxmodernaacomparativestudyoftheparticulate AT medinacastilloantoniol analysingtheinusestabilityofmrnalnpcovid19vaccinescomirnatypfizerandspikevaxmodernaacomparativestudyoftheparticulate AT perezroblesraquel analysingtheinusestabilityofmrnalnpcovid19vaccinescomirnatypfizerandspikevaxmodernaacomparativestudyoftheparticulate AT navasnatalia analysingtheinusestabilityofmrnalnpcovid19vaccinescomirnatypfizerandspikevaxmodernaacomparativestudyoftheparticulate |